GLP-1 drugs have moved beyond the doctor’s office - reshaping grocery habits with major implications for FMCG
The usage and consideration of GLP-1 weight loss drugs is growing rapidly. As a result, new shopper behaviours are forming – putting basket volume, consumption habits, brand loyalty, and more, at risk for brands, manufacturers and retailers. Understanding these behavioural shifts is key to future-proofing your portfolio and adapting to evolving habits.
Re-introducing our PanelVoice syndicated study: Uncovering the impact of GLP-1 medication on GB households
Now in its second year, our PanelVoice syndicated GLP-1 drugs study reveals how awareness, motivation, and usage of these weight-loss drugs are actively reshaping how consumers shop, eat, and engage across the FMCG landscape.
Built for FMCG brands, manufacturers, retailers, and beyond, the report combines attitudinal insight with real GB purchasing behaviour to help you understand who’s using GLP-1 drugs, who’s discontinuing - and what it all means for you.
Now is the time to act: decode these emerging patterns and use them to build smarter, more resilient strategies.
What you’ll get from the study
Close critical knowledge gaps
Understand how Users, Lapsers, and Considerers think, behave, and evolve - with real-world insights into adoption triggers, barriers, and projected appetite across consumer groups - so you can identify relevant opportunities and connect with shoppers throughout their journey.
Turn insight into innovation
GLP-1 usage triggers major shifts in shopping behaviours across categories and channels. Track how GLP-1 usage is reshaping category habits, shopping missions, and channel behaviour — then use it to drive innovation, NPD, and strategy.
Plan with confidence in a volatile market
GLP-1 drug use and consideration is accelerating. Future proof your business and give your teams the tools to act faster. Back your decisions with real-world data to strengthen retail conversations and navigate the future with clarity.Key questions answered, include:
- Who are the Users, Lapsed, and Considerers — and how are they different?
- Why are Users and Lapsers adopting GLP-1 drugs?
- What’s preventing broader GLP-1 drugs uptake?
- How is usage impacting food, drink, and alcohol consumption?
- How many households are open to trying the drugs?
- How are people discovering and evaluating the drugs?
- How have attitudes and behaviours changed over the past year?
- What’s the potential future size of this consumer base?
What makes this study different
- The only GB study to connect attitudinal survey data with real shopper behaviour
- 11K surveyed | 3.8K screened and tracked via our GB panel
- Segmentation includes: Users, Lapsed Users, Considerers
- Highlights the key segments you need to prioritise now
Pricing
Two packages are available, starting from £9,850.
The full insight suite, including Parts 1 and 2, is available for £15,000.
- Part 1: Awareness, attitudes, sizing and demographic insights
- Part 2: In-depth GLP-1 drug user behaviour, category & retailer choice, and grocery-level basket analysis. Only available as an add-on to Part 1
Available from 21 May.
Contact us to speak to an expert and find the right option for your needs.